BioCryst Pharmaceuticals, Inc.
$9.19
▼
-3.84%
2026-04-21 05:36:00
www.biocryst.com
NMS: BCRX
Explore BioCryst Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.3 B
Current Price
$9.19
52W High / Low
$11.31 / $6
Stock P/E
8.7
Book Value
$-0.56
Dividend Yield
—
ROCE
107.2%
ROE
-88.68%
Face Value
—
EPS
$1.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
435
Beta
0.69
Debt / Equity
-3.68
Current Ratio
2.06
Quick Ratio
2.03
Forward P/E
11.92
Price / Sales
2.74
Enterprise Value
$2.6 B
EV / EBITDA
7.41
EV / Revenue
2.97
Rating
Strong Buy
Target Price
$21.4
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
| 2. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 3. | PRF Technologies Ltd. | $2.64 | — | $2.31 M | — | -53.59% | -90.37% | $17.95 / $1.8 | $10.29 |
| 4. | SIGA Technologies, Inc. | $4.57 | 14.06 | $327.41 M | 0% | 11.76% | 11.23% | $9.62 / $4.29 | $2.78 |
| 5. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 6. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 7. | ANI Pharmaceuticals, Inc. | $81.73 | 23.13 | $1.81 B | 0.06% | 6.99% | 16.16% | $99.5 / $56.71 | $25.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 406.56 M | 159.4 M | 163.35 M | 145.53 M | 131.53 M | — |
| Operating Profit | 260.38 M | 29.59 M | 29.79 M | 21.23 M | -4.51 M | — |
| Net Profit | 245.84 M | 12.9 M | 5.08 M | 0.03 M | -26.8 M | — |
| EPS in Rs | 0.98 | 0.05 | 0.02 | 0 | -0.11 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 874.84 M | 450.71 M | 331.41 M | 270.83 M |
| Operating Profit | 340.99 M | -2.54 M | -103.71 M | -148.44 M |
| Net Profit | 263.86 M | -88.88 M | -226.54 M | -247.12 M |
| EPS in Rs | 1.05 | -0.35 | -0.9 | -0.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 514.16 M | 490.42 M | 516.96 M | 550 M |
| Total Liabilities | 633.31 M | 966.35 M | 972.49 M | 844.6 M |
| Equity | -119.15 M | -475.93 M | -455.53 M | -294.6 M |
| Current Assets | 404.35 M | 421.97 M | 495.97 M | 516.5 M |
| Current Liabilities | 196.07 M | 160.38 M | 149.99 M | 105.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 347.37 M | -52.02 M | -95.14 M | -161.85 M |
| Investing CF | -13.69 M | 52.59 M | -131.5 M | -128.24 M |
| Financing CF | -349.93 M | -5.76 M | 32.48 M | 88.03 M |
| Free CF | 344.9 M | -53.14 M | -97.31 M | -163.2 M |
| Capex | -2.47 M | -1.12 M | -2.17 M | -1.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 36% | 22.37% | — | — |
| Earnings Growth % | 60.77% | 8.33% | — | — |
| Profit Margin % | -19.72% | -68.36% | -91.24% | — |
| Operating Margin % | -0.56% | -31.29% | -54.81% | — |
| Gross Margin % | 97.28% | 98.65% | 97.57% | — |
| EBITDA Margin % | 2.84% | -35.1% | -53.12% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.